Gbh

Quick links to important sections

Gbh

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gbh

Property Description
Active ingredient Lindane (gamma-HCH)
Form Topical (Lotion, Cream, Shampoo)
Pharmacological class Ectoparasiticide and Ovicide
General use Eliminates external parasitic infestations
Origin Synthetic Organochlorine Chemical

Gbh: Classification, Composition, and Origin

Gbh is a medicinal preparation defined by its active ingredient, Lindane, which is formally classified as an ectoparasiticide and ovicide used strictly for external application. This agent belongs to the distinct chemical class of organochlorine chemicals and is a synthetic compound chemically identified as the gamma isomer of hexachlorocyclohexane (gamma-HCH). The drug's efficacy as a parasite-killing agent is clinically recognized and supported by pharmacological studies.

For therapeutic purposes, the medication is prepared exclusively for topical use in various pharmaceutical forms, including a lotion, cream, or shampoo. The preparation is designed to deliver the potent gamma-HCH directly to the infested site, minimizing broad systemic exposure while concentrating the effect locally.

What is the General Purpose of Lindane-Containing Preparations?

The general purpose of a product containing Lindane is the comprehensive eradication of external parasitic infestations in humans. The medicine is commonly utilized as a specialized treatment in scenarios involving stubborn lice infestations or persistent cases of scabies. This is achieved through the parasiticidal action of the drug, which functions as a neurotoxin to eliminate parasites.

Crucially, the preparation also demonstrates potent ovicidal action, meaning it is designed to kill the parasite ova (eggs) as well, thereby breaking the life cycle of the infestation. Regulatory labeling confirms that Lindane is reserved for specific patient populations or as a second-line option when safer agents have failed, confirming its reserved status.

Is Gbh a Single or Combination Product?

Lindane is primarily a single-ingredient active substance, differentiating it from formulations that may combine multiple primary ectoparasiticides. The product base is designed to suit topical delivery, using an inert vehicle such as an emulsion or detergent base. While the core active entity remains Lindane, some commercial variants may be designated as a combination product because they include a secondary, non-parasiticidal ingredient, such as the antiseptic agent Cetrimide, which is intended to address associated dermal conditions.

What side effects are possible with Gbh?

Possible Side Effects and Safety Information

The safety profile of Gbh is primarily defined by the risk of Central Nervous System (CNS) depression, which is the basis for key regulatory restrictions on the medicine's use.

Adverse Reaction Scope

The most frequently documented adverse reactions often involve the CNS and Gastrointestinal systems. Regulatory documentation notes common events such as dizziness, nausea, somnolence, and headache.

System-Organ Classes Involved

The principal body systems affected are the Nervous System (e.g., altered consciousness, amnesia) and the Respiratory, Thoracic and Mediastinal system (e.g., difficulty breathing).

Serious Adverse Reactions

Serious outcomes documented in regulatory sources include respiratory depression, coma, seizures, and profound amnesia. These are generally associated with higher exposures, overdose, or concurrent use of other depressant substances.

Safety-Related Restrictions

Due to significant risks of misuse, abuse, and dependence, Gbh formulations are subject to a strict Risk Evaluation and Mitigation Strategy (REMS) program mandated by the FDA. This regulatory requirement restricts access to the medicine, requiring certified prescribers and enrolled pharmacies to manage safety risks effectively.

Population-Specific and Exposure-Related Notes

Safety documents explicitly warn against the co-administration with alcohol or other CNS depressants, as this combination substantially increases the risk of severe, life-threatening CNS and respiratory depression. The risk of overdose and toxicity is considered dose-dependent.

Overdose and Emergency Response

Overdose and When to Seek Help

Lindane (gamma-HCH) overdose is documented by regulatory authorities as primarily involving Central Nervous System (CNS) toxicity, typically resulting from accidental ingestion, misuse, or over-application.

Documented Manifestations and Severe Outcomes

Overexposure is associated with signs of CNS hyperexcitability, including seizures (convulsions), tremor, unsteadiness, headache, dizziness, nausea, and vomiting. Severe poisoning is a serious regulatory concern, potentially leading to respiratory failure, coma, and death. Rarer but life-threatening outcomes such as cardiac arrhythmia have also been officially documented.

Emergency Response and Management

Regulatory labeling mandates that individuals seek immediate medical attention or call emergency services immediately upon suspected overdose, particularly if symptoms like trouble breathing, inability to be awakened, or seizures occur. Official documents state that no specific antidote is known for Lindane poisoning. Management is strictly symptomatic and supportive, focusing on maintaining the airway, controlling seizures using approved anticonvulsants, and considering gastric decontamination following oral ingestion.

Population-Specific Overdose Considerations

The risk of severe neurotoxicity is officially noted to be increased in specific populations, including infants and young children, individuals weighing less than 50 kg, and patients with a history of seizure disorders or compromised skin integrity. These patients require heightened vigilance regarding systemic absorption and signs of toxicity.

Therapeutic Uses of Gbh

Therapeutic Indications and Benefits of Gbh

Gbh is primarily utilized in clinical settings to address specific neurological and sleep-related disorders. Its mechanism of action involves interacting with neurotransmitter systems in the brain to modulate central nervous system activity, leading to several distinct therapeutic outcomes.

Management of Narcolepsy Symptoms

The primary use of Gbh is in the management of narcolepsy, a chronic neurological condition that affects the brain's ability to control sleep-wake cycles. It is specifically used to address two major symptoms:

  • Cataplexy: This involves sudden, temporary loss of muscle tone often triggered by strong emotions. Gbh helps reduce the frequency and intensity of these episodes.
  • Excessive Daytime Sleepiness (EDS): Gbh is used to improve alertness during the day in patients who experience overwhelming urges to sleep or sudden sleep attacks, which are hallmarks of the condition.

Improvement of Sleep Architecture

Beyond managing daytime symptoms, Gbh has a significant impact on nocturnal sleep patterns. Patients with narcolepsy often experience fragmented and poor-quality nighttime sleep. The use of Gbh is associated with:

  • Increased Deep Sleep: It promotes an increase in slow-wave sleep (stages 3 and 4), which is considered the most restorative phase of the sleep cycle.
  • Consolidated Sleep: By reducing nighttime awakenings, it helps create a more continuous and stable sleep structure.

Secondary Effects on Daily Functioning

By addressing the core symptoms of sleep disorders, Gbh can contribute to broader improvements in a patient's daily life. These benefits are typically observed over long-term use and include:

  • Enhanced Cognitive Alertness: Improved sleep quality and reduced daytime sleepiness often lead to better concentration and focus.
  • Stabilized Mood: Reducing the burden of chronic sleep deprivation and the unpredictability of cataplexy can lead to a more stable emotional state.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Gbh (Lindane)

The use of Lindane (Gbh) is highly restricted by regulatory bodies, designated only as a second-line agent for lice and scabies. This means it is permissible only for patients who have failed or cannot tolerate safer, first-line treatments.

Category Official Regulatory Statement
Populations for Whom Use is Contraindicated Premature infants; Individuals with known uncontrolled seizure disorders; Patients with Crusted (Norwegian) Scabies or other skin conditions (e.g., Atopic Dermatitis, Psoriasis) that increase systemic absorption; Individuals with a known hypersensitivity to the drug; Patients with open wounds or broken skin [FDA Labeling].
Age-Related Eligibility Rules Contraindicated in premature infants. Use requires caution in infants, children, and the elderly due to higher risk of neurotoxicity.
Physiological/Clinical Status Pregnancy: Use is generally not recommended. Lactation: Breastfeeding must be interrupted, and milk must be discarded for at least 24 hours after use [NIH MedlinePlus].
Condition-Specific Restrictions Use with caution in individuals weighing less than 110 lbs (50 kg). Careful consideration is required for patients with a history of head trauma, severe hepatic cirrhosis, CNS tumors, or HIV/AIDS [FDA Labeling].
Retreatment Retreatment is prohibited after a single course due to the risk of cumulative toxicity [FDA Labeling].

Connection to the overall eligibility profile: Regulatory documentation strictly defines the eligible population, reserving the medicine for treatment failure only. Eligibility is further structured by absolute contraindications that exclude groups based on seizure risk or vulnerable physiology, such as premature infants and those with compromised skin barriers. These restrictions are mandatory to manage the severe neurological risk associated with Lindane.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medicine's interaction profile is primarily defined by the risk of additive neurotoxicity and factors that increase systemic exposure via the skin, based on official regulatory documentation.

Interacting Agents and Conditions

The most significant documented interaction is pharmacodynamic reinforcement with medicinal products that lower the seizure threshold. These interacting product categories include Antipsychotics, Antidepressants, Theophylline, and certain Antibiotics (e.g., quinolones, imipenem), as co-administration increases the risk of CNS toxicity.

Exposure-Altering Interactions

Systemic exposure is increased by Exposure-Altering Pharmacokinetic Interactions with topical substances. The use of oils, oil-based creams, ointments, or hair dressings is documented to enhance percutaneous absorption of Lindane, a major regulatory caution. Similarly, compromised skin conditions like crusted scabies or psoriasis are contraindications because they dramatically increase systemic absorption.

Regulatory Restrictions

  • Contraindicated Combination Status: Use is strictly prohibited in patients with uncontrolled seizure disorders or severe skin conditions that increase absorption, as specified in regulatory labels.
  • Population-Specific Notes: Infants, children, the elderly, and individuals weighing under 50 kg are identified in official documents as populations with a greater risk of serious neurotoxicity, intensifying the severity of any interaction.

Mechanism of Action

The mechanism of Gbh action is centered on modulating core inhibitory and regulatory pathways within the central nervous system (CNS). Gbh achieves this by engaging defined biological targets, leading to a cascade of inhibitory actions that result in the inhibition of overactive signaling.

Targeted Receptor and Neurotransmitter Modulation

Gbh acts as an agonist on both GABA-B receptors and its own high-affinity GHB receptors. The binding at these primary biological targets initiates a direct alteration in neurotransmitter dynamics, particularly enhancing inhibitory signaling. This engagement of key regulatory systems induces a shift toward reduced neuronal firing frequency in specific neuronal networks.

Downstream Regulation of Neural Cascades

The activation of these receptors triggers a presynaptic inhibition cascade. This molecular event significantly reduces the release of several other neurotransmitters—including excitatory ones—across multiple synapses. This widespread control over mediator release results in the modulation of downstream signaling activity, establishing a regulated state within targeted neural systems.

Dosage and Administration Information

How to Use Lindane (Gbh) — Official Administration Guidelines

The use of Lindane (Gbh) is governed by strict, standardized protocols that specify the route, duration, and dose. The product is designated strictly for topical administration as a single-course treatment for external parasites. The lotion form is utilized for cutaneous application, while the shampoo form is for the hair and scalp.

Instruction Detail
Dosing Schedule Single Application Only. The maximum volume for the single treatment is 60 mL (2 fluid ounces) of the 1% preparation. It is explicitly stated that re-treatment is prohibited.
Preparation The product must be applied to clean, cool, dry skin or hair that is free of other lotions, creams, or oils. A minimum of one hour after bathing is required before application can commence.
Duration (Lotion) The 1% Lotion must remain on the skin for 8 to 12 hours; it must be completely washed off immediately thereafter and never remain on for longer than 12 hours.
Duration (Shampoo) The 1% Shampoo must be left on the hair for 4 minutes only before rinsing thoroughly with warm water.

Procedural Structure

The administration protocol mandates strict adherence to application conditions and disposal rules. For the scabies indication, the 1% Lotion is to be applied in a thin layer over all skin from the neck down. For lice, the 1% Shampoo is applied to dry hair up to the 60 mL limit, if necessary. The application site must not be covered with any non-breathable materials. Following the mandated contact time, any product remaining in the single-use container must be immediately discarded. Caution is advised when prescribing this medication to individuals weighing less than 50 kg (110 lbs).

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored the effects in several areas. The available data comes primarily from Phase 3 clinical trials and post-marketing observational studies.


Core Study Findings

Pain Management

One study investigated an outcome related to inflammation in affected tissues. The study investigated the effect on pain scores. Outcomes were measured using a visual analogue scale (VAS) at scheduled intervals over a three-month period.

  • A Phase 3 trial investigated the drug's role in chronic back pain management.
  • Another trial reported a change in symptom severity over a 6-month period, and the study reported a significant difference between the drug and placebo groups.

Combination Therapy

One study evaluated the combination of this drug and physiotherapy, using mobility scores as the primary measure. The primary endpoint was the change in a standardized mobility score after eight weeks.

  • Research investigated whether the combination was associated with changes in sleep quality in patients with related conditions.
  • In one study, specific focus was placed on the adverse event reporting when the two treatments were administered together.

Safety and Tolerability Profiles

Studies have reviewed the adverse events and safety data associated with the drug's use. The data covers both short-term and long-term exposure.

  • Patients with a history of heart conditions were excluded from or had specific outcomes tracked in this treatment study. The reasons for exclusion were outlined in the study protocol.
  • One study investigated the frequency of recurrence of a related condition in long-term use compared to short-term use.
  • A separate study evaluated the study subjects with chronic pain, focusing on recorded adverse events over a two-year period.

Overall, further research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Gbh (FAQ)

Q: What's the typical time it takes for Gbh to start working?

A: Gbh is a topical treatment designed to kill parasites and eggs during its specific contact time (which ranges from 4 minutes to 12 hours depending on the form). Official regulatory guidance notes that even after a successful application, residual itching may continue for a few weeks, and this does not necessarily mean the treatment has failed. Concerns may be discussed with a healthcare provider.


Q: How long does the effect of one dose of Gbh usually last?

A: This medication is only prescribed as a single, one-time application course to eradicate the existing infestation. Because of toxicity risks, regulatory standards strictly prohibit re-treatment. Regulatory protocols often involve a follow-up to confirm that the infestation is fully cleared.


Q: What happens if you miss a dose of Gbh?

A: Since Gbh is a single, one-time application, the concept of a 'missed dose' does not apply as it is not taken regularly. If the initial application was somehow incomplete or removed too early, official guidance states that re-treatment is prohibited, and a healthcare provider should be contacted.


Q: Can taking Gbh make my condition feel worse before it gets better?

A: According to official product information, the itch associated with scabies may sometimes feel worse after applying Lindane Lotion. This is not a sign of treatment failure, and the regulation prohibits using more of the medication. Persistent concerns can be discussed with a healthcare provider.


Q: Is Gbh safe to use during pregnancy or while breastfeeding?

A: Lindane is generally not recommended for use during pregnancy. If it is used while breastfeeding, official guidelines state that the mother’s milk must be discarded for at least 24 hours after the application. Regulatory guidance suggests a healthcare professional may consider a safer alternative treatment.


Q: Does Gbh cause weight gain or loss?

A: Official regulatory safety information for this product does not list weight gain or weight loss among the commonly or rarely reported adverse events.


Q: How does Gbh affect your mood or mental state?

A: Adverse events involving the nervous system include dizziness, altered consciousness, and amnesia. In severe cases or overdose, seizures have been documented. Strict adherence to administration instructions is necessary to manage these risks.


Q: Is it possible to become dependent on Gbh?

A: Official regulatory documents identify a potential risk of misuse, abuse, and dependence associated with the drug. Because of the serious risks, the FDA mandates a strict Risk Evaluation and Mitigation Strategy (REMS) program to control its access and usage.


Q: Can Gbh affect your ability to concentrate or drive?

A: Since the medication can cause dizziness and altered consciousness, the official labeling suggests that activities requiring concentration, such as driving a car or operating machinery, may be impaired. Caution is advised regarding activities that require concentration after application.


Q: What should I do if I experience a very rare side effect from Gbh?

A: If concerning or rare side effects are experienced, the label advises contacting a physician or healthcare provider immediately. Patients are also encouraged to report adverse events directly to the appropriate regulatory authority, such as the FDA.


Q: Does Gbh have any known effect on liver function?

A: Lindane is metabolized primarily by the liver, and because of this, regulatory warnings advise caution when prescribing the medication to patients with a history of severe liver conditions, such as hepatic cirrhosis.


Q: Do children ever get prescribed Gbh?

A: Gbh is typically reserved for adults and patients who weigh at least 110 lbs (50 kg). While its use may be considered in children when other treatments fail, official documentation mandates extreme caution due to a higher risk of serious neurotoxicity. Its use is contraindicated in premature infants.


Q: What is the maximum amount of time I can take Gbh?

A: As a topical treatment, the duration of use is strictly limited to the product's contact time. The lotion must be completely washed off after 8 to 12 hours and cannot remain on the skin longer than 12 hours. The shampoo must be washed off after only 4 minutes. It is a single treatment only.


Q: Does Gbh come in different forms (like liquid or tablet)?

A: This medication is only prepared for external, topical use. It is available in various forms for application to the skin or hair, including a lotion, a cream, and a shampoo.


Q: Are the side effects of Gbh the same for everyone?

A: No, the risk profile is not uniform for every individual. Regulatory warnings explicitly state that the risk of serious neurotoxicity is greater in vulnerable populations, including infants, young children, the elderly, and individuals weighing under 50 kg (110 lbs).


Q: Does Gbh need to be taken with food or on an empty stomach?

A: Gbh is exclusively for external use as a topical product applied to the skin or hair. It is not an oral medication and is therefore not taken with food or on an empty stomach.


Q: Is Gbh used to treat chronic pain?

A: No. According to the official regulatory indications, Gbh is approved strictly for the treatment of external parasitic infestations, specifically lice and scabies. It is not listed for the management of chronic pain.


Q: Can I take Gbh with common cold or flu medicines?

A: The primary regulatory warning regarding interactions involves medicines that lower the seizure threshold, such as certain antidepressants and antipsychotics. If you are taking cold or flu medicines, a healthcare professional should be consulted for a complete interaction check.


Q: Are there any long-term side effects associated with Gbh use?

A: Gbh is not intended for long-term use. Due to the risk of cumulative toxicity, regulatory restrictions strictly limit the product to a single application only, and re-treatment is prohibited.


Q: Does Gbh cause changes in sleep patterns?

A: Official adverse event reports list somnolence (drowsiness). Because of this common central nervous system effect, the medication may potentially influence a person's sleep patterns.


Q: How is Gbh eliminated from the body?

A: After being absorbed through the skin, the active ingredient Lindane is primarily eliminated from the body by undergoing metabolism in the liver. This process involves dechlorination pathways.


Q: What if Gbh doesn't seem to be working for me after a few weeks?

A: The label states that persistent itching alone may not mean treatment has failed. If the infestation appears to persist, it is necessary to contact a doctor for follow-up, as using the product more than once is prohibited due to toxicity risks.


Q: Can Gbh make me feel dizzy or light-headed?

A: Yes, dizziness is listed as a common adverse reaction in official regulatory documents. This effect is related to the drug's activity on the Central Nervous System.


Q: What's the evidence supporting the benefits of Gbh?

A: The regulatory approval of Gbh is based on clinical data that demonstrated the drug's effectiveness. These studies confirmed its potent action as an ectoparasiticide and ovicide for eradicating lice and scabies infestations.


Q: Why is Gbh sometimes mentioned as a 'date rape' drug (clarification question)?

A: Gbh is subject to significant regulatory control due to its recognized potential for misuse, abuse, and dependence. Because of the serious risks, including profound amnesia and altered consciousness, the FDA mandates a strict Risk Evaluation and Mitigation Strategy (REMS) program.

How should Gbh be stored and disposed of?

The storage and disposal of Lindane (GHB) preparations are governed by strict regulatory rules due to their neurotoxicity risk and organochlorine composition.

Mandatory Storage and Protection

The product must be stored at room temperature (typically 20 C to 25 C) in its original, tightly closed container. It is mandatory to store the medicine away from heat, moisture, and direct light, and it must not be frozen. Due to the risk of accidental poisoning, the medication must be kept out of the sight and reach of children and pets in a secure location.

Disposal of Unused Product

Lindane is a regulated substance, and leftover product must be immediately discarded after the single application is complete; do not save it for later. The official disposal instructions specify that the medicine should not be thrown away via wastewater (i.e., not flushed down the toilet or poured down a sink) or standard household trash. Disposal must be in accordance with local hazardous waste or pharmaceutical take-back regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Gbh found in:

A-Z Index: